Dr Jeffrey Paul Fennelly, MD in Ayer, MA - General Practice

Dr Jeffrey Paul Fennelly, MD is a General Practice physician based in Ayer, Massachusetts. Dr Jeffrey Paul Fennelly is licensed to practice in New York (license number 301389) and his current practice location is 42 Patton Rd, Ayer, Massachusetts. He can be reached at his office (for appointments etc.) via phone at (781) 555-1212.

NPI number for Dr Jeffrey Paul Fennelly is 1760770531 and his current mailing address is 42 Patton Rd, Ayer, Massachusetts. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1760770531.

Contact Information

	Dr Jeffrey Paul Fennelly, MD
	42 Patton Rd, Ayer, MA 01434-3802
	(781) 555-1212
	Not Available

Physician's Profile

Full Name	Dr Jeffrey Paul Fennelly
Gender	Male
Speciality	General Practice
Location	42 Patton Rd, Ayer, Massachusetts
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1760770531
Provider Enumeration Date: 07/14/2011
Last Update Date: 05/17/2021

Medical Identifiers

Medical identifiers for Dr Jeffrey Paul Fennelly such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1760770531	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	301389 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Jeffrey Paul Fennelly is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Jeffrey Paul Fennelly, MD 42 Patton Rd, Ayer, MA 01434-3802 Ph: (781) 555-1212	Dr Jeffrey Paul Fennelly, MD 42 Patton Rd, Ayer, MA 01434-3802 Ph: (781) 555-1212

News Archive

Dauntless, Aegis sign licensing agreement for Intravail drug delivery technology

Dauntless Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC today announced a licensing agreement providing Dauntless' access to Aegis' Intravail drug delivery technology for an undisclosed oncology application and an option for three additional drugs.

Eliminating ABCB5-expressing cells crucial for successful colorectal cancer treatment

Researchers at Children's Hospital Boston have found a marker called ABCB5 that both tags a small proportion of cells within colorectal cancers and fuels resistance in those cells to standard treatments. The results indicate that eliminating ABCB5-expressing cells is crucial for successful colorectal cancer treatment, while adding to the growing body of evidence for a theory of cancer growth called the cancer stem cell hypothesis.

New technology for measuring heart rate via a conventional wrist watch

SPO Medical Inc. (SPOM) announced today that it has successfully demonstrated to several leading sports and fitness watch manufacturers its vital sign technology for measurement of the heart rate via a conventional wrist watch, negating the need of the traditional chest strap currently used by most sports watch manufacturers.

New hope for premature babies with breathing troubles

Babies start breathing in the womb, inhaling and exhaling irregularly at first, and then gradually more and more, until the day when they're born and have to do it all the time. But premature babies sometimes have trouble. They stop breathing periodically, sometimes for 20 or 30 seconds at a time.

Dr Jeffrey Paul Fennelly, MD - General Practice in Ayer, MA